JPWO2022049310A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022049310A5 JPWO2022049310A5 JP2023515289A JP2023515289A JPWO2022049310A5 JP WO2022049310 A5 JPWO2022049310 A5 JP WO2022049310A5 JP 2023515289 A JP2023515289 A JP 2023515289A JP 2023515289 A JP2023515289 A JP 2023515289A JP WO2022049310 A5 JPWO2022049310 A5 JP WO2022049310A5
- Authority
- JP
- Japan
- Prior art keywords
- copolymer
- repeat units
- pharmaceutical composition
- mol
- solid oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20194828 | 2020-09-07 | ||
| EP20194828.8 | 2020-09-07 | ||
| EP20208628 | 2020-11-19 | ||
| EP20208628.6 | 2020-11-19 | ||
| PCT/EP2021/074625 WO2022049310A1 (en) | 2020-09-07 | 2021-09-07 | Improved pharmaceutical formulations of glp-1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541827A JP2023541827A (ja) | 2023-10-04 |
| JP2023541827A5 JP2023541827A5 (https=) | 2024-09-13 |
| JPWO2022049310A5 true JPWO2022049310A5 (https=) | 2024-09-13 |
Family
ID=77821779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515289A Pending JP2023541827A (ja) | 2020-09-07 | 2021-09-07 | Ｇｌｐ－１受容体アゴニストの改善された医薬製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240041983A1 (https=) |
| EP (1) | EP4210680A1 (https=) |
| JP (1) | JP2023541827A (https=) |
| CN (1) | CN116419750A (https=) |
| WO (1) | WO2022049310A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| EP4429704A4 (en) | 2021-11-10 | 2025-11-05 | I2O Therapeutics Inc | IONIC LIQUID COMPOSITIONS |
| EP4486366A1 (en) * | 2022-03-03 | 2025-01-08 | Cyprumed GmbH | Improved oral pharmaceutical formulations of therapeutic peptides and proteins |
| WO2023209662A1 (en) * | 2022-04-29 | 2023-11-02 | Pentide Therapeutics Limited | Pharmaceutical compositions of semaglutide and the methods of use thereof |
| CA3266547A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | COMPOSITIONS FOR ORAL ADMINISTRATION |
| WO2024134493A1 (en) * | 2022-12-19 | 2024-06-27 | Quisitive Therapeutics | Drug delivery system for tirzepatide |
| US12605427B2 (en) * | 2023-05-15 | 2026-04-21 | Red Mountain Med Spa, LLC | Sublingual semaglutide-BPC 157 combination for weight loss |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219656A (en) | 1963-08-12 | 1965-11-23 | Rohm & Haas | Alkylpolyalkoxyalkyl glucosides and process of preparation therefor |
| US3839318A (en) | 1970-09-27 | 1974-10-01 | Rohm & Haas | Process for preparation of alkyl glucosides and alkyl oligosaccharides |
| AT382381B (de) | 1984-10-02 | 1987-02-25 | Oesterr Zuckerfab Evidenz | Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate |
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| EP1062240B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| JP2002512175A (ja) | 1998-02-27 | 2002-04-23 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−１類似体の誘導体類 |
| EP1061946B1 (en) | 1998-02-27 | 2004-04-28 | Novo Nordisk A/S | Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
| JP2003522099A (ja) | 1998-02-27 | 2003-07-22 | ノボ ノルディスク アクティーゼルスカブ | 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン |
| EP1175390B1 (en) | 1999-04-05 | 2005-02-02 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| MXPA06006745A (es) | 2003-12-18 | 2006-08-18 | Novo Nordisk As | Compuestos glp-1 novedosos. |
| JP2007537142A (ja) | 2003-12-18 | 2007-12-20 | ノボ ノルディスク アクティーゼルスカブ | アルブミン様物質に結合した新規のｇｌｐ−１類似物 |
| MXPA06015049A (es) | 2004-07-08 | 2007-02-08 | Novo Nordisk As | Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol. |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| US8030273B2 (en) | 2004-10-07 | 2011-10-04 | Novo Nordisk A/S | Protracted exendin-4 compounds |
| US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
| JP5755398B2 (ja) | 2005-03-18 | 2015-07-29 | ノヴォ ノルディスク アー／エス | 伸長されたｇｌｐ−１化合物 |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| WO2009030774A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| RU2548807C2 (ru) | 2009-05-20 | 2015-04-20 | Торэй Индастриз, Инк. | Пептиды, проникающие в клетку |
| ES2659442T3 (es) | 2009-09-30 | 2018-03-15 | Thiomatrix Forschungs- Und Beratungs Gmbh | Polímeros mucoadhesivos con estructuras parciales de vitamina B |
| WO2011133198A1 (en) | 2010-04-21 | 2011-10-27 | Hosheng Tu | A pharmaceutical composition of nanoparticles |
| GB2501219A (en) | 2011-02-04 | 2013-10-16 | Aegis Therapeutics Llc | Orally bioavailable peptide drug compositions and methods thereof |
| WO2012140155A1 (en) | 2011-04-14 | 2012-10-18 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| SG11201402400YA (en) * | 2011-11-30 | 2014-06-27 | Takeda Pharmaceutical | Dry coated tablet |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| EP2861220A2 (en) | 2012-06-14 | 2015-04-22 | Entrega, Inc. | Mucoadhesive devices for delivery of active agents |
| US20150273069A1 (en) * | 2012-10-17 | 2015-10-01 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| US10265384B2 (en) * | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| CN105832691B (zh) * | 2016-05-31 | 2018-10-02 | 深圳市健元医药科技有限公司 | 一种度拉糖肽结肠定位缓释制剂及其制备方法 |
| US20200237875A1 (en) * | 2019-01-30 | 2020-07-30 | Synlev Pharmaceuticals Corporation | Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders |
-
2021
- 2021-09-07 WO PCT/EP2021/074625 patent/WO2022049310A1/en not_active Ceased
- 2021-09-07 JP JP2023515289A patent/JP2023541827A/ja active Pending
- 2021-09-07 US US18/043,976 patent/US20240041983A1/en active Pending
- 2021-09-07 EP EP21773092.8A patent/EP4210680A1/en active Pending
- 2021-09-07 CN CN202180075206.9A patent/CN116419750A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2025204821A1 (en) | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant | |
| JP6379143B2 (ja) | エクセナチドの経口投与用の方法及び組成物 | |
| US20220370366A1 (en) | Tablets containing cilofexor and pharmaceutically acceptable carriers | |
| US8454999B2 (en) | Sustained release compositions of alfuzosin | |
| JP2022093381A (ja) | リナグリプチンおよびメトホルミンの組合せ | |
| CN112512633A (zh) | 使用gip/glp1共激动剂用于治疗的方法 | |
| Niman et al. | A review on the efficacy and safety of oral semaglutide | |
| JP2006528152A5 (https=) | ||
| CN101031305A (zh) | 类风湿性关节炎的预防和/或治疗药物 | |
| JP2005528430A5 (https=) | ||
| JPWO2022049310A5 (https=) | ||
| JP2018527374A5 (https=) | ||
| EP4161525A1 (en) | The process for the preparation of a film coated tablet comprising linagliptin and metformin | |
| JP6232630B2 (ja) | 骨系統疾患治療薬及びその用途 | |
| CA2620065A1 (en) | Methods and formulations for modulating lyn kinase activity and treating related disorders | |
| Game | Novel hypoglycaemic agents: considerations in patients with chronic kidney disease | |
| US20240366596A1 (en) | Treatment of hfpef in post-menopausal women with an sgc stimulator | |
| Pote et al. | Comparative clinical pharmacokinetics and pharmacodynamics of investigational once-daily sustained-release (sr) vildagliptin 100 mg tablet formulation with conventional 50 mg twice-daily regimen in healthy Indian males | |
| JPWO2023006923A5 (https=) | ||
| US20250152527A1 (en) | Therapeutic combinations of colchicine and methods of using same | |
| Sahay et al. | Incretin-based Therapy during Ramadan Fasting | |
| TW202535374A (zh) | 用於預防及/或治療肝疾病之組合療法 | |
| US20140294950A1 (en) | Methods of treating obesity in responder and non-responder populations | |
| Duan et al. | Pharmacotherapy of Obesity and Metabolic Syndrome | |
| CA3235787A1 (en) | Methods of treating patients having type 1 diabetes with eflornithine |